ZERION
A pharmaceutical company aspiring to transform the pharmaceutical landscape for formulation of poorly soluble drugs that are currently not reaching their therapeutic potential.
| Date | Investors | Amount | Round |
|---|---|---|---|
| investor | €0.0 | round | |
| investor | €0.0 | round | |
* | N/A | DKK8.2m | Late VC |
| Total Funding | 000k | ||
| DKK | 2020 | 2021 | 2022 | 2023 | 2024 |
|---|---|---|---|---|---|
| Revenues | 0000 | 0000 | 0000 | 0000 | 0000 |
| % growth | - | - | 69 % | 9 % | (3 %) |
| EBITDA | 0000 | 0000 | 0000 | 0000 | 0000 |
| Profit | 0000 | 0000 | 0000 | 0000 | 0000 |
| % profit margin | - | (576 %) | (576 %) | (312 %) | (6 %) |
| EV | 0000 | 0000 | 0000 | 0000 | 0000 |
| EV / revenue | 00.0x | 00.0x | 00.0x | 00.0x | 00.0x |
| EV / EBITDA | 00.0x | 00.0x | 00.0x | 00.0x | 00.0x |
| R&D budget | 0000 | 0000 | 0000 | 0000 | 0000 |
Source: Company filings or news article
Related Content
Zerion Pharma is a pharmaceutical startup that operates in the drug formulation sector. The company has developed a proprietary technology called Dispersome®, which is designed to increase the solubility and dissolution rate of poorly soluble small molecule drugs. This technology aims to improve the bioavailability of drugs, leading to better therapeutic outcomes and increased convenience for patients.
Zerion's Dispersome® technology works by formulating these drugs into stable amorphous formulations with a high drug load. This means that the drugs are transformed into a form that dissolves more readily in the body, allowing for more efficient absorption and effectiveness. The Dispersome® formulations are compatible with standard solid oral dosage form manufacturing processes and facilities, making them easy to integrate into existing pharmaceutical production lines.
Zerion Pharma serves clients in the pharmaceutical industry, including prominent companies that have adopted the Dispersome® technology. The company's business model is based on establishing partnerships with these companies, providing them with the technology to improve their drug formulations. This, in turn, positively impacts patient well-being and advances drug solubility.
The company generates revenue through these partnerships, likely through licensing agreements or royalties from the use of the Dispersome® technology. Zerion is also involved in research and development, with its first Cannabidiol drug formulation set to enter clinical studies in 2024.
Keywords: Zerion Pharma, Dispersome® technology, drug formulation, pharmaceutical industry, partnerships, drug solubility, bioavailability, therapeutic outcomes, patient convenience, research and development.